Merck KGaA (MKGAY), the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics (SWTX), Reuters’ Sabrina Valle and Patricia Weiss, citing to people familiar with the matter. If the talks are successful, a deal could be signed in the coming weeks, the three sources said. Shares of SpringWorks have advanced about 13% to $45.50 in Monday morning trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- Merck KGaA in talks to buy SpringWorks Therapeutics, Reuters reports
- Merck KGaA in advanced talks to acquire SpringWorks Therapeutics, Reuters says
- SpringWorks Therapeutics up 13% following Reuters report of takeover talks
- SpringWorks Therapeutics trading halted, volatility trading pause
- SpringWorks should be bought on weakness, says JPMorgan